•T cell engagers are an exciting new therapeutic modality which has seen multiple approvals in recent years
•In solid tumours progress has been slower due to difficulties in finding the right balance between activity and toxicity
•The design and affinities of T cell engagers need to the modulated to find the right therapeutic window and unlock this class of therapeutics in solid tumour
MIGUEL GASPAR, Senior Director, Oncology R&D, AstraZeneca
